



27 August 2025

cyclopharm
technegas
ultralute

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Cyclopharm 1H 2025 Results Webinar

Cyclopharm Limited (ASX: CYC), a global leader in functional lung ventilation imaging, will host a webinar to discuss the Company's half-year results for the period ended 30 June 2025.

The 30-minute webinar will commence at **11:00am (AEST) on Tuesday 2 September 2025** and will include:

- Overview of the 1H 2025 financial results;
- Update on U.S. commercialisation progress; and
- Outlook on expanding clinical opportunities for Technegas®.

All shareholders and investors are invited to attend. Please register at the following link:

https://us02web.zoom.us/webinar/register/WN_iWJGbWTRRN6WLHc2Q25Vkw

Once registered, participants will receive full details on how to join the webinar.

ENDS

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary Cyclopharm
Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.